Precision Therapeutics
for Brain Diseases
Kynexis is advancing the first precision medicine for the treatment of cognitive impairment associated with schizophrenia (CIAS).
Our Purpose
We’re taking a new approach to improve everyday function and quality of life by treating cognitive impairment in people with schizophrenia.
A significant challenge in improving the lives of people with Schizophrenia has been developing a treatment for CIAS, which is a major remaining and currently untreated cause of disability for the 24 million people worldwide that are affected by the disease.
The dysregulation of kynurenic acid causes cognitive impairment for nearly 40% of people living with Schizophrenia, which is why we’re taking a biomarker-based approach to enable the selection of patients who will most likely benefit most from this therapy.
Classifying the underlying biology associated with cognitive impairment associated with schizophrenia (CIAS) to create a precision medicine to improve cognition.
For decades, patients diagnosed with psychiatric disorders have received diagnoses based solely on their presenting disease characteristics, and not accounting for the biology drivers of the disease. Using a proprietary database created by our founders, we’re leveraging artificial intelligence to look at common biomarkers, genetics, and the underlying biology to redefine the diagnosis and identify relevant biomarkers associated with CIAS.
Targeting a key mechanism in the kynurenine pathway
We’re taking a precision approach to target KAT-II, a key enzyme in the kynurenine. KYN-5356 is a first-in-class small molecule that is a potent and highly selective KAT-II inhibitor, solving the challenges of previous attempts with KAT-II inhibition.
APPROACH
Management Team
Peter Hongaard
Executive Chairman
Kees Been
CEO
Thomas Rasmussen
Interim CEO
First Lastname
CMO
BOD
Peter Hongaard
Executive Chairman
Christer Kohler
Founding Director
Dmitrij Hristodorov
Investor Director
Raul Martin-Ruiz
Investor Director
Tim Lohoff, Ph.D.
Board Observer
Salvatore Scaffidi, Ph.D.
Board Observer
SAB
Professor Robert Schwartz
Ph.D.
Professor Carol Tamminga
M.D
Leadership
Latest News
Tackling brain diseases with a diverse and broad team of industry experts.
At Kynexis, we’re working to pioneer the next era of treatments for brain diseases by advancing the first precision medicine for cognitive impairment associated with schizophrenia. Harnessing the power of artificial intelligence, our foundational science is the driving force behind our mission to transform the treatment paradigm of schizophrenia.
If you want to learn more about the work at Kynexis, or are interested in joining our team of trailblazers, contact us.
Contact
